Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
Mestag Therapeutics Appoints Professor Ton Logtenberg as Chair
Mestag Therapeutics, an immunotherapy company harnessing new insights into fibroblast-immune interactions in cancer and inflammatory […]
Synaptogenix Announces Topline Results from NIH-Sponsored Phase 2 Clinical Trial of Bryostatin-1 for Advanced Alzheimer's Disease
Synaptogenix, an emerging biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, has announced topline data […]
UK Pharmacists Able to Supply Alternative Penicillin to Treat Strep A
Serious Shortage Protocols (SSPs) have been issued across the United Kingdom for three penicillin medicines […]
Sosei Heptares and Lilly Enter Multi-target Collaboration and License Agreement in Diabetes and Metabolic Diseases
Sosei Group Corporation announces it has entered a drug discovery collaboration with Eli Lilly and […]
Viome Life Sciences Unveils CancerDetect™, the Future of Oral and Throat Cancer Detection
Viome Life Sciences, a mission-driven biotechnology company, announces the arrival of its CancerDetect™ test for oral […]
New Two-year Data Confirm Roche’s Vabysmo Improves Vision With Fewer Treatments for People With Neovascular Age-related Macular Degeneration
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new two-year data from the TENAYA and […]
Exact Sciences Presents First Time Data Detailing Ability to Predict Radiation Therapy Benefit in Breast Cancer Patients
Exact Sciences, a leading provider of cancer screening and diagnostic tests, today shared initial clinical […]
Erasca Announces Exclusive Worldwide License for Pan-RAF Inhibitor Naporafenib
Erasca, a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for […]
Horizon Therapeutics Announces First Subject Dosed in Phase 1 Trial Evaluating HZN-457 for the Treatment of Gout
Horizon Therapeutics has announced the first subject has been dosed in a Phase 1 randomized, […]
Generate Biomedicines Demonstrates a Novel Method of Reducing Immunogenicity through Protein Re-surfacing
Generate Biomedicines has announced that it has published data in the peer-reviewed journal Frontiers in […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more